CCR7 and hepatocellular carcinoma: In the only human phase 1 of CAR T cells published in HCC [60], CAR T-cell products were monitored by flow cytometry and were predominantly terminally differentiated effector memory T cells (CD45RA+/CCR7−; mean, 78.2%) and effector memory T cells (CD45R-CCR7-; mean, 14.1%; range, 0.8–47.4%).